Microcap Ledger Werewolf Therapeutics, Inc. $HOWL
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 48,599,066 [10-Q 2026-07-31]
What the company doesAI summary of filing
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated immunotherapies for cancer and immune-mediated diseases using its proprietary PREDATOR platform. The company's lead programs are WTX-124, a conditionally activated IL-2 molecule in Phase 1/1b clinical trials, and WTX-330, a conditionally activated IL-12 molecule in Phase 1b/2 clinical trials, along with preclinical candidates WTX-712, WTX-518, WTX-921, WTX-1011, and WTX-2022. Werewolf has licensed its interferon alpha INDUKINE molecule JZP898 to Jazz Pharmaceuticals and generates revenue through that collaboration. The company is pre-revenue from product sales and is currently exploring strategic alternatives, including potential sale, merger, or licensing arrangements, to extend its capital resources. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$9.86M | −$3.97M | $21.99M | [S-4 2026-09-22] |
| FY ended Dec 2025 | — | −$60.82M | −$60.29M | $57.05M | [S-4 2026-09-22] |
| FY ended Dec 2024 | — | −$70.52M | −$56.19M | $111.00M | [S-4 2026-09-22] |
- Quarterly cash burn
- −$1.98M
- Cash runway Estimate
- ~33.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 44,563,153 | [10-Q 2024-11-07] |
| 2025-03-05 | 44,827,159 | [10-K 2025-03-11] |
| 2025-05-02 | 44,873,646 | [10-Q 2025-05-08] |
| 2025-08-08 | 45,728,999 | [10-Q 2025-08-14] |
| 2025-10-29 | 48,540,200 | [10-Q 2025-11-04] |
| 2026-03-20 | 48,596,817 | [10-K 2026-03-27] |
| 2026-05-01 | 48,596,817 | [10-Q 2026-05-07] |
| 2026-07-27 | 48,599,066 | [10-Q 2026-07-31] |
- Shelf registration
- S-3 filed 2025-05-08; declared effective 2025-05-15 [S-3 2025-05-08]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-02-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-02-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-06] |
| 2025-10-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-06] |
| 2025-05-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-15] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-07 | Evnin Luke | sell | 107,429 | $0.31 | [4 2026-07-08] |
| 2026-07-06 | Evnin Luke | sell | 35,770 | $0.32 | [4 2026-07-08] |
| 2026-06-29 | Evnin Luke | sell | 157,084 | $0.30 | [4 2026-06-29] |
| 2026-06-17 | Ra Capital Management, L.P. | sell | 389,216 | $0.35 | [4 2026-06-22] |
| 2026-06-17 | Ra Capital Management, L.P. | sell | 27,695 | $0.35 | [4 2026-06-22] |
| 2026-06-16 | Ra Capital Management, L.P. | sell | 139,686 | $0.37 | [4 2026-06-16] |
| 2026-06-16 | Ra Capital Management, L.P. | sell | 9,939 | $0.37 | [4 2026-06-16] |
| 2026-06-15 | Ra Capital Management, L.P. | sell | 120,216 | $0.39 | [4 2026-06-16] |
| 2026-06-15 | Ra Capital Management, L.P. | sell | 8,554 | $0.39 | [4 2026-06-16] |
| 2026-06-12 | Ra Capital Management, L.P. | sell | 159,119 | $0.40 | [4 2026-06-16] |
| 2026-06-12 | Ra Capital Management, L.P. | sell | 11,322 | $0.40 | [4 2026-06-16] |
| 2026-06-11 | Ra Capital Management, L.P. | sell | 245,066 | $0.38 | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-21 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-21 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-08-20 | 8-K | Material agreement entered |
| 2026-07-31 | 10-Q | Quarterly report |
| 2026-07-31 | 8-K | Results of operations |
| 2026-07-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-26 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-22 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $HOWL
Email me when Werewolf Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.